SLAM
AXSM icon

Swiss Life Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Swiss Life Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$656K Buy
2,679
+414
+18% +$89.8K ﹤0.01% 833
2026
Q1 		$383K Buy
2,265
+689
+44% +$119K ﹤0.01% 985
2025
Q4 		$288K Buy
+1,576
New +$220K ﹤0.01% 1045

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Swiss Life Asset Management's AXSM Position: Q2 2026 in Review

Swiss Life Asset Management increased its Axsome Therapeutics (AXSM) stake by 18% in Q2 2026, buying an estimated $89.8K and bringing the position to 2,679 shares worth $656K. The position accounts for ﹤0.01% of the portfolio, ranked #833.

Swiss Life Asset Management first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 294 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Swiss Life Asset Management held 2,679 shares of Axsome Therapeutics worth $656K as of Q2 2026.
  • Swiss Life Asset Management bought 414 Axsome Therapeutics shares in Q2 2026, an estimated $89.8K.
  • Axsome Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #833 holding.
  • Swiss Life Asset Management first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 294 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.